<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present a case of <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e> in a young patient whose typical ECG pattern was 'masked' after ibutilide was administered for <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> cardioversion </plain></SENT>
<SENT sid="1" pm="."><plain>Ibutilide, a class III antiarrhythmic agent used for the treatment of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and flutter, prolongs the action potential duration plateau phase by augmenting the slow component of the inward <z:chebi fb="0" ids="29101">Na(+)</z:chebi> current and by blocking the rapid component of the delayed rectifier <z:chebi fb="120" ids="26216">potassium</z:chebi> current </plain></SENT>
<SENT sid="2" pm="."><plain>Insights into the pathophysiology of <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e> and this first-reported action of ibutilide are supplied, providing a plausible scientific basis for the masking effect of ibutilide </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, issues concerning the safety of ibutilide administration in patients with <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e> along with the importance of programmed ventricular stimulation and especially short-long-short sequence protocol in inducing <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> in these patients are also discussed </plain></SENT>
</text></document>